Abeona Therapeutics Inc (NASDAQ:ABEO) Stake Cut by Barclays PLC

Barclays PLC decreased its holdings in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 28.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 55,000 shares of the biopharmaceutical company’s stock after selling 21,394 shares during the period. Barclays PLC owned about 0.13% of Abeona Therapeutics worth $348,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. abrdn plc grew its position in shares of Abeona Therapeutics by 158.8% during the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after buying an additional 200,647 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after acquiring an additional 429,456 shares during the period. Western Standard LLC grew its holdings in shares of Abeona Therapeutics by 7.0% during the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after purchasing an additional 110,998 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Abeona Therapeutics during the 3rd quarter worth approximately $84,000. Finally, Rosalind Advisors Inc. lifted its holdings in shares of Abeona Therapeutics by 4.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after purchasing an additional 82,000 shares during the last quarter. 80.56% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Stock Performance

Shares of ABEO opened at $5.22 on Monday. The firm has a market capitalization of $226.91 million, a PE ratio of -1.94 and a beta of 1.46. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm has a 50-day moving average price of $5.86 and a 200 day moving average price of $5.71. Abeona Therapeutics Inc has a 52-week low of $3.05 and a 52-week high of $9.01.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ABEO shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research note on Monday, November 25th. Finally, StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 9th.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.